Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus.

Lucidi P, Porcellati F, Cioli P, Candeloro P, Marinelli Andreoli A, Bolli GB, Fanelli CG.

Diabetes Technol Ther. 2020 Jan;22(1):57-61. doi: 10.1089/dia.2019.0231. Epub 2019 Nov 13.

PMID:
31411498
2.

Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes.

Reginato E, Pippi R, Aiello C, Sbroma Tomaro E, Ranucci C, Buratta L, Bini V, Marchesini G, De Feo P, Fanelli C.

J Clin Med. 2019 Jun 14;8(6). pii: E851. doi: 10.3390/jcm8060851.

3.

Real-time continuous glucose monitoring decreases the risk of severe hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia.

Lucidi P, Porcellati F, Bolli GB, Fanelli CG.

Ann Transl Med. 2018 Dec;6(Suppl 2):S97. doi: 10.21037/atm.2018.11.23. No abstract available.

4.

A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes.

Nicolucci A, Prosperini G, Buzzetti R, De Cosmo S, Fanelli CG, Napoli R, Giorgino F; AGERE Study Group.

Minerva Endocrinol. 2018 Dec;43(4):501-510. doi: 10.23736/S0391-1977.18.02850-X. Review.

PMID:
30463398
5.

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.

Porcellati F, Lucidi P, Candeloro P, Cioli P, Marinelli Andreoli A, Curti G, Bolli GB, Fanelli CG.

Diabetes Care. 2019 Jan;42(1):85-92. doi: 10.2337/dc18-0706. Epub 2018 Oct 10.

PMID:
30305345
6.

Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology.

Lucidi P, Porcellati F, Bolli GB, Fanelli CG.

Curr Diab Rep. 2018 Aug 18;18(10):83. doi: 10.1007/s11892-018-1065-6. Review.

PMID:
30121746
7.

Plasma Insulin Levels and Hypoglycemia Affect Subcutaneous Interstitial Glucose Concentration.

Moscardó V, Bondia J, Ampudia-Blasco FJ, Fanelli CG, Lucidi P, Rossetti P.

Diabetes Technol Ther. 2018 Apr;20(4):263-273. doi: 10.1089/dia.2017.0219. Epub 2018 Mar 12.

PMID:
29638161
8.

Effects of an Intensive Lifestyle Intervention to Treat Overweight/Obese Children and Adolescents.

Ranucci C, Pippi R, Buratta L, Aiello C, Gianfredi V, Piana N, Reginato E, Tirimagni A, Chiodini E, Sbroma Tomaro E, Gili A, De Feo P, Fanelli C, Mazzeschi C.

Biomed Res Int. 2017;2017:8573725. doi: 10.1155/2017/8573725. Epub 2017 Jun 5.

10.

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins.

Porcellati F, Lucidi P, Bolli GB, Fanelli CG.

Diabetes Care. 2015 Dec;38(12):2237-40. doi: 10.2337/dc15-1848. No abstract available.

PMID:
26604278
11.

Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.

Lucidi P, Porcellati F, Marinelli Andreoli A, Carriero I, Candeloro P, Cioli P, Bolli GB, Fanelli CG.

Diabetes Care. 2015 Dec;38(12):2204-10. doi: 10.2337/dc15-0801. Epub 2015 Sep 10.

PMID:
26358287
12.

Low Levels of Unmodified Insulin Glargine in Plasma of People With Type 2 Diabetes Requiring High Doses of Basal Insulin.

Lucidi P, Porcellati F, Yki-Järvinen H, Riddle MC, Candeloro P, Marinelli Andreoli A, Bolli GB, Fanelli CG.

Diabetes Care. 2015 Jul;38(7):e96-7. doi: 10.2337/dc14-2662. No abstract available.

PMID:
26106233
13.

Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.

Porcellati F, Lucidi P, Cioli P, Candeloro P, Marinelli Andreoli A, Marzotti S, Ambrogi M, Bolli GB, Fanelli CG.

Diabetes Care. 2015 Mar;38(3):503-12. doi: 10.2337/dc14-0649. Epub 2014 Dec 18.

PMID:
25524950
14.

Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes.

Porcellati F, Lucidi P, Bolli GB, Fanelli CG.

Diabetes Care. 2013 Dec;36(12):3860-2. doi: 10.2337/dc13-2088. No abstract available.

15.

Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes.

Lucidi P, Porcellati F, Rossetti P, Candeloro P, Andreoli AM, Cioli P, Hahn A, Schmidt R, Bolli GB, Fanelli CG.

Diabetes Care. 2012 Dec;35(12):2647-9. doi: 10.2337/dc12-0271. Epub 2012 Oct 18.

16.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
17.

Fatty liver index, gamma-glutamyltransferase, and early carotid plaques.

Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, Gastaldelli A, Ferrannini E; RISC Investigators.

Hepatology. 2012 May;55(5):1406-15. doi: 10.1002/hep.25555.

PMID:
22334565
18.

Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.

Porcellati F, Lucidi P, Rossetti P, Candeloro P, Andreoli AM, Marzotti S, Cioli P, Bolli GB, Fanelli CG.

Diabetes Care. 2011 Dec;34(12):2521-3. doi: 10.2337/dc11-1064. Epub 2011 Oct 4.

19.

Pharmacokinetics and pharmacodynamics of basal insulins.

Porcellati F, Bolli GB, Fanelli CG.

Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S15-24. doi: 10.1089/dia.2011.0038. Review.

PMID:
21668333
20.

Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.

Bolli GB, Lucidi P, Porcellati F, Fanelli CG.

Diabetes Care. 2011 May;34 Suppl 2:S220-4. doi: 10.2337/dc11-s224. No abstract available.

Supplemental Content

Loading ...
Support Center